{"ticker": {"uuid": "b1965408-5d3b-4689-960f-f662ca543006", "symbol": "ONCIN", "name": "Oncoinvent ASA", "exchange": "OSL", "country": "NO", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Oncoinvent reaches halfway point in ovarian cancer trial enrollment By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNRFNRdzNQQWhVMHQtN1lWcnJUc04zcnRVVF93MV8tSDdKaEhTY2lvemgzcFRFb0RBelZXYUE3dDRwRmtLN1BYY2FkSGtLbl8zTGhORjRzdlUyWW9ldWJiRy1MTTh6b09uRk5Id1F4dU5PbE05UzhmZEhEd2t6eG9wbkNrUWprMnZVNjRvMWdSZzRYWGlseUJMSVltaV80Q2tlN2tjSHpTSkZXdUxfZ1hRdU5OUjhqdGlSQ2VFLTZFNUg3TDRyVDZF?oc=5", "source_name": "Investing.com UK", "published_at": "2026-06-18T05:34:00+00:00", "published_display": "18 Jun 2026 05:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncoinvent ASA: Share capital decrease completed", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPN1drOGJTV2E4d001bHpubDJpb2ZhOGFHbFFsTWpESWppWl94RkJnU3VqbVczR1RnTnhoNHpZSU10ZVk1WG5waW8yMGN6X2tXRUJrcDlpZ3dzMjBQenBZUlFxSGRwSGxGNmFna2pVRzNxNGhIVFYzbFFMc19XSUxXd0paaUx0bEZtcF81aUxNV19ERmZVeWhBVXo5ZkVqVXVtODN2bndkOVN2VUhUTFFseEdKRVpfWWczQVJXWm1ONDVKTUFCUWo4czNuRWVGN01fLUdn?oc=5", "source_name": "Finansavisen", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAJBVV95cUxQOC11N09BTnpYZWZqT3liZzV2cHdsT3VEOWlRbVdTbVFZY01SSE40NlVzTll4U3NYV1dKbnpaX1l2R2g4SFYxb0lxYzNhZ0xIbTRteklPVVhDcFd3bDNfcnhXRHAycUhUWnM2U2dtT05TanhoLUtJY1ZKMXI4RzR1YzA0cl9ZR3JTejN4RUk5WXVNSUE4anU5Y29BVGlyMkNPaXJsYkhlcEU3SXBSU2g2WVNfV3BreW1ybGs2NWhLNUVoVFpTOGpLR2tuUXd4Y0tJYXpJdGpSU2VLX3FFQk9JTmtkWGlucVlOYmN0ajQ3ZE1CSnRNUVg2dGg3WmtIUGlLSjFRbmVjN1c0TFZkSFNIN2xKMGpGLWp1RHU0QUl5OGZHTG4zaUJBcnRlRVNXcFpyRkFWOVVkWjlnaEs0eURqaVd3ckw?oc=5", "source_name": "TradingView", "published_at": "2025-06-30T07:00:00+00:00", "published_display": "30 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCIN Stock Price and Chart \u2014 OSL:ONCIN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5XZkI4cEFPWUJUZ2FkN1F6YVhCcjZ0YUJLUGxqbnVFQ3VyemJwU1NEZzVoNmYtX0RQUjFFM2tIWWFWT1hoQm5nTnE0ZVctWDlJNE9ROHpYdWljZw?oc=5", "source_name": "TradingView", "published_at": "2024-12-13T10:52:45+00:00", "published_display": "13 Dec 2024 10:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncoinvent ASA announces oversubscribed private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQVlhmTTVrXzB4eWp6MHNwLWR1cFM0QXJYSE8zcW5uRDRyOFRKaEgtbmRPVTVCdkRydVVGVDlQSjc2bHVyTHI0YVRHWGVNNEttZW8wcUY4Z0JtTnJ4ZWVZREMyR2NQSHgxQVlGRWVqTFd0LV9CejI3S2RZWXBWbklremlsTUNIMUh6MjlBaExoNkQ?oc=5", "source_name": "BeBeez International", "published_at": "2024-12-05T08:00:00+00:00", "published_display": "05 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNWml6Mk9XX0c5V3BteWFhY1Fpb2RrSnZXc1N6TGtES1B0VWdhTWwteDVkZjNjUjVidFhYYWFCMnJrQnh2S0NPNU5oQ19tYVEwSGloZzAwbDJzVy1WU1hXU2c5cVNuZUJpNW5CVUd1Nk15UmxOQkpzNFRsWUVGVjdBcDdSbmFLNWl6OEJIelRfa1ZmMk9KS2xTUkdHZU1UV2dRSTJJdVBBTXVJZHRnUi1MR3kwdDY0V2c5NkRNaHU2bno4LWhwZ1plYVd3Y0ppcTQ?oc=5", "source_name": "BioSpace", "published_at": "2024-12-04T08:00:00+00:00", "published_display": "04 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Oncoinvent reaches halfway point in ovarian cancer trial enrollment By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNRFNRdzNQQWhVMHQtN1lWcnJUc04zcnRVVF93MV8tSDdKaEhTY2lvemgzcFRFb0RBelZXYUE3dDRwRmtLN1BYY2FkSGtLbl8zTGhORjRzdlUyWW9ldWJiRy1MTTh6b09uRk5Id1F4dU5PbE05UzhmZEhEd2t6eG9wbkNrUWprMnZVNjRvMWdSZzRYWGlseUJMSVltaV80Q2tlN2tjSHpTSkZXdUxfZ1hRdU5OUjhqdGlSQ2VFLTZFNUg3TDRyVDZF?oc=5", "source_name": "Investing.com UK", "published_at": "2026-06-18T05:34:00+00:00", "published_display": "18 Jun 2026 05:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncoinvent ASA: Share capital decrease completed", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPN1drOGJTV2E4d001bHpubDJpb2ZhOGFHbFFsTWpESWppWl94RkJnU3VqbVczR1RnTnhoNHpZSU10ZVk1WG5waW8yMGN6X2tXRUJrcDlpZ3dzMjBQenBZUlFxSGRwSGxGNmFna2pVRzNxNGhIVFYzbFFMc19XSUxXd0paaUx0bEZtcF81aUxNV19ERmZVeWhBVXo5ZkVqVXVtODN2bndkOVN2VUhUTFFseEdKRVpfWWczQVJXWm1ONDVKTUFCUWo4czNuRWVGN01fLUdn?oc=5", "source_name": "Finansavisen", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAJBVV95cUxQOC11N09BTnpYZWZqT3liZzV2cHdsT3VEOWlRbVdTbVFZY01SSE40NlVzTll4U3NYV1dKbnpaX1l2R2g4SFYxb0lxYzNhZ0xIbTRteklPVVhDcFd3bDNfcnhXRHAycUhUWnM2U2dtT05TanhoLUtJY1ZKMXI4RzR1YzA0cl9ZR3JTejN4RUk5WXVNSUE4anU5Y29BVGlyMkNPaXJsYkhlcEU3SXBSU2g2WVNfV3BreW1ybGs2NWhLNUVoVFpTOGpLR2tuUXd4Y0tJYXpJdGpSU2VLX3FFQk9JTmtkWGlucVlOYmN0ajQ3ZE1CSnRNUVg2dGg3WmtIUGlLSjFRbmVjN1c0TFZkSFNIN2xKMGpGLWp1RHU0QUl5OGZHTG4zaUJBcnRlRVNXcFpyRkFWOVVkWjlnaEs0eURqaVd3ckw?oc=5", "source_name": "TradingView", "published_at": "2025-06-30T07:00:00+00:00", "published_display": "30 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCIN Stock Price and Chart \u2014 OSL:ONCIN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5XZkI4cEFPWUJUZ2FkN1F6YVhCcjZ0YUJLUGxqbnVFQ3VyemJwU1NEZzVoNmYtX0RQUjFFM2tIWWFWT1hoQm5nTnE0ZVctWDlJNE9ROHpYdWljZw?oc=5", "source_name": "TradingView", "published_at": "2024-12-13T10:52:45+00:00", "published_display": "13 Dec 2024 10:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncoinvent ASA announces oversubscribed private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQVlhmTTVrXzB4eWp6MHNwLWR1cFM0QXJYSE8zcW5uRDRyOFRKaEgtbmRPVTVCdkRydVVGVDlQSjc2bHVyTHI0YVRHWGVNNEttZW8wcUY4Z0JtTnJ4ZWVZREMyR2NQSHgxQVlGRWVqTFd0LV9CejI3S2RZWXBWbklremlsTUNIMUh6MjlBaExoNkQ?oc=5", "source_name": "BeBeez International", "published_at": "2024-12-05T08:00:00+00:00", "published_display": "05 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNWml6Mk9XX0c5V3BteWFhY1Fpb2RrSnZXc1N6TGtES1B0VWdhTWwteDVkZjNjUjVidFhYYWFCMnJrQnh2S0NPNU5oQ19tYVEwSGloZzAwbDJzVy1WU1hXU2c5cVNuZUJpNW5CVUd1Nk15UmxOQkpzNFRsWUVGVjdBcDdSbmFLNWl6OEJIelRfa1ZmMk9KS2xTUkdHZU1UV2dRSTJJdVBBTXVJZHRnUi1MR3kwdDY0V2c5NkRNaHU2bno4LWhwZ1plYVd3Y0ppcTQ?oc=5", "source_name": "BioSpace", "published_at": "2024-12-04T08:00:00+00:00", "published_display": "04 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 57, "total_relevant": 6, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 6, "score": 50, "total": 6, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 2.75, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 49.0, "latest_week": "2026-06-19", "one_week_move": 11.9, "four_week_move": 6.5, "twelve_week_move": 6.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.065413, "market_dynamics_buy_signal": false, "relative_strength": -26.320612, "fair_value_gap": -90.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 39.4678, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+11.9% over one week, +6.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 2}, {"label": "Investing.com UK", "count": 1}, {"label": "Finansavisen", "count": 1}, {"label": "BeBeez International", "count": 1}, {"label": "BioSpace", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 6}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 5}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "6", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+11.9% over one week, +6.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Oncoinvent reaches halfway point in ovarian cancer trial enrollment By Investing.com"}], "updated_at": "2026-06-22T20:27:34.183962+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}